Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16743435 | 0.93 | MEN1 (0.35) | MEN1KMT2APOLBLMNAHPGD | |
| SCHEMBL843885 | 0.92 | POLB (0.38) | MEN1KMT2APOLBLMNAHPGD | |
| SCHEMBL13058913 | 0.89 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL16743439 | 0.86 | MEN1 (0.32) | MEN1KMT2APOLBLMNAHPGD | |
| SCHEMBL16743445 | 0.85 | MAPT (0.37) | MEN1KMT2APOLBLMNAHPGD | |
| SCHEMBL844828 | 0.83 | MEN1 (0.45) | MEN1KMT2ALMNAHPGDRAB9A | |
| SCHEMBL844555 | 0.83 | NPSR1 (0.39) | MEN1KMT2APOLBLMNAHPGD | |
| SCHEMBL16998641 | 0.81 | MEN1 (0.33) | MEN1KMT2APOLBLMNAHPGD | |
| SCHEMBL16743432 | 0.80 | ALDH1A1 (0.32) | POLBALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL844534 | 0.80 | MEN1 (0.36) | MEN1KMT2APOLBLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315521-B2 | Pyrimidines as novel therapeutic agents | UNIVERSITé LAVAL (CA) | 2016-04-19 | — | — | US | disclosed |
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITé LAVAL (CA) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225423-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | MEN1 4378/4885KMT2A 3590/4885POLB 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.